Home
About Us
Our activities
News & Events
Publications
Contact us
Reserved area
Work with us

Leading global and impactful child health research

This content is password protected. To view it please enter your password below:

Password:

Contacts

Torre di Ricerca Pediatrica
Corso Stati Uniti 4
35127 Padova
Italy

VAT 04150680280

info@penta-id.org

fondazionepenta@pec.it

+39 049 964 0122

@Penta_ID

Fondazione Penta Onlus

penta_childhealthresearch

Penta Child Health Research

Newsletter

Recent publications

Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets
2 days ago
The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus
2 weeks ago
Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study
2 weeks ago
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
1 month ago

Tweets by Penta_ID

We use cookies to ensure that we give you the best experience on our website. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie law inside the PENTA Privacy Policy. If you continue to use this site we will assume that you are happy with it.
Ok Read more

Leading global and impactful child health research

Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial